Highlights
- Smith & Nephew will release its third-quarter trading report before the market opens this week, followed by an analyst call at midday.
- The medical technology group recently refinanced, pricing a new US dollar bond, buying back part of its notes due at the start of the decade and redeeming an earlier tranche.
- The sterling amount of the interim dividend was fixed in late October, putting the payment date within reach for UK holders.
Smith & Nephew
steps into the spotlight this week with its third-quarter trading report due before the opening bell, the first operating update since the medical device maker completed a round of balance-sheet housekeeping in the autumn. For investors who follow the Healthcare Stocks theme, it is one of the more instructive stories on the London market right now.
The FTSE 100 company, which makes hip and knee implants, sports medicine instruments and advanced wound care products, has spent the past year trying to convince shareholders that its multi-year turnaround plan is delivering durable margin gains.
What the market wants to hear this week
The orthopaedics division remains the key test. Investors will look for evidence that US hip an...